Farrell High School students are raising awareness for an important cause--donating blood for sickle cell anemia.

ROANOKE, Va. – Ensuring no one fights alone. The Carilion Clinic Sickle Cell Collaborative is holding a walk to honor sickle cell patients and their caregivers on Saturday. Sickle cell disease is a ...

Sickle cell anemia refers to a group of genetic blood disorders that affect a person’s levels of hemoglobin, the protein in ...

NASHVILLE, Tenn. (WTVF) — One of Vanderbilt's latest studies has found a cure for sickle cell disease. Sickle cell is a blood disorder where the body creates mutated red blood cell proteins. It often ...

CHICAGO (WLS) -- Sherrell Johnson, 43, is a force to be reckoned with. She calls herself the "Sickle Cell Diva." "I don't let sickle cell run me," Johnson said. "I run sickle cell." She's lived with ...

Because SCD can impair blood and oxygen delivery to any part of the body, it can cause a wide range of complications, including anemia, blood clots, and stroke. It can also damage organs, such as the ...

A Black female doctor when that was rare, she developed a diagnostic test for the disease that is still a standard tool, as well as treatment guidelines.

LOS ANGELES (KABC) -- It's been more than a month since the FDA approved two milestone gene-editing treatments for sickle cell disease, but lining up patients for these therapies will be a challenge ...

Memantine, a long-approved and cost-effective drug used to treat Alzheimer's disease, could also benefit patients with sickle cell anemia in the future. Initial clinical data from an international ...

September Is Sickle Cell Awareness Month. While many people are familiar with sickle cell anemia, sickle cell traits have also plagued our community. Sickle cell trait (SCT) is an inherited blood ...

Sickle cell disease (SCD) can affect people of any ethnicity but is much more common among Africans and African Americans. Other ethnic groups with higher rates of SCD include Hispanic Americans from ...

Pfizer Inc. (NYSE:PFE) on Friday released results from the Phase 3 THRIVE-131 study evaluating inclacumab, an investigational P-selectin inhibitor, in patients 16 years of age and older with sickle ...